1. Valassi E, Santos A, Yaneva M et al. The European Registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 2011;165:383–92.)
  2. Lacroix A, Feelders RA, Stratakis CA et al. Cushing’s syndrome. Lancet 2015;386:913–27.
  3. Cortisol: What it is, function, symptoms & levels. Cleveland Clinic. (n.d.). Retrieved February 17, 2023, from,and%20carbohydrates%2C%20or%20your%20metabolism
  4. Pivonello, Rosario, et al. “Cushing’s disease: the burden of illness.” Endocrine 56 (2017): 10-18.
  5. Ceccato, Filippo, et al. “Screening tests for Cushing’s syndrome: urinary free cortisol role measured by LC-MS/MS.” The Journal of Clinical Endocrinology & Metabolism 100.10 (2015): 3856-3861.
  6. Kreitschmann-Andermahr et al. Eur J Endocrinol 2015;172:285
  7. Isturisa® Summary of Product Characteristics. May 2020.
  8. Nieman LK, Biller BM, Findling JW et al. Treatment of Cushingʼs syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100:2807–31.
  9. Fleseriu M, Auchus R, Bancos I et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol 2021;9:847–75.
  10. Braun, Leah T., et al. “Recurrence after pituitary surgery in adult Cushing’s disease: a systematic review on diagnosis and treatment.” Endocrine 70 (2020): 218-231.
  11. Lonser, Russell R., Lynnette Nieman, and Edward H. Oldfield. “Cushing’s disease: pathobiology, diagnosis, and management.” Journal of neurosurgery 126.2 (2017): 409
  12. Amandine Ferriere, Antoine Tabarin. Cushing’s syndrome: Treatment and new therapeutic approaches.Best Practice and Research: Clinical Endocrinology and Metabolism, 2020, 34, pp.101381-. 10.1016/
  13. Santos, Alicia, et al. “Quality of life in patients with Cushing’s disease.” Frontiers in endocrinology 10 (2019): 862.
  14. Rakovec, M., Zhu, W., Khalafallah, A.M. et al. Patient reported outcomes and treatment satisfaction in patients with cushing syndrome. Endocrine 79, 161–170 (2023).
  15. Acree, Rachel, et al. “Patient and provider perspectives on postsurgical recovery of Cushing syndrome.” Journal of the Endocrine Society 5.8 (2021): bvab109.
  16. Dekkers OM, Horvath-Puho E, Jorgensen JO et al. Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab 2013;98:2277–84.
  17. Lindholm J, Juul S, Jorgensen JO et al. Incidence and late prognosis of Cushingʼs syndrome: a population-based study. J Clin Endocrinol Metab 2001;86:117–23.
  18. Papoian V, Biller BM, Webb SM, Campbell KK, Hodin RA, Phitayakorn R. Patients’ perception on clinical outcome and quality of life after a diagnosis of Cushing syndrome. Endocr Pract. 2016;22(1):51-67
  19. Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, Geer EB. Predictors of mortality and long-term outcomes in treated Cushing’s disease: a study of 346 patients. J Clin Endocrinol Metab. 2013 Mar;98(3):1022-30. doi: 10.1210/jc.2012-2893. Epub 2013 Feb 7. PMID: 23393167; PMCID: PMC3590483.
  20. Feelders RA, Pulgar SJ, Kempel A et al. The burden of Cushingʼs disease: clinical and health-related quality of life aspects. Eur J Endocrinol 2012;167:311–26.
  21. Pivonello R, De Leo M, Cozzolino A et al. The treatment of Cushingʼs disease. Endocr Rev 2015;36:385–486.
  22. Pendharkar AV, Sussman ES, Ho AL, Hayden Gephart MG, Katznelson L. Cushing’s disease: predicting long-term remission after surgical treatment. Neurosurg Focus 2015; 38: E13.
  23. Patil CG, Prevedello DM, Lad SP, et al. Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 2008; 93: 358–62.
  24. Dzialach, Lukasz et al. “Cushing’s syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia.” Hormones (Athens, Greece) vol. 21,4 (2022): 735-742. doi:10.1007/s42000-022-00397-4
  25. Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 2011;96:1992–2003.
  26. Biller BM, Grossman AB, Stewart PM et al. Treatment ofadrenocorticotropin-dependent Cushingʼs syndrome: a consensus statement. J Clin Endocrinol Metab 2008;93:2454–62.
  27. Assie G, Bahurel H, Coste J et al. Corticotroph tumor progression after adrenalectomy in Cushingʼs disease: a reappraisal of Nelsonʼs syndrome. J Clin Endocrinol Metab 2007;92:172–9.
  28. Hinojosa-Amaya JM, Cuevas-Ramos D, Fleseriu M. Medical management of Cushingʼs syndrome: current and emerging treatments. Drugs 2019;79:935–56.
  29. Bengtsson D, Ragnarsson O, Berinder K, Dahlqvist P, Edén Engström B, Ekman B, Höybye C, Järås J, Valdemarsson S, Burman P, Wahlberg J. Increased Mortality Persists after Treatment of Cushing’s Disease: A Matched Nationwide Cohort Study. J Endocr Soc. 2022 Mar 18;6(6):bvac045. doi: 10.1210/jendso/bvac045. PMID: 35480633; PMCID: PMC9037134.
  30. Badia X, Valassi E, Roset M, Webb SM. Disease-specific quality of life evaluation and its determinants in Cushing’s syndrome: what have we learnt? Pituitary. 2014 Apr;17(2):187-95. doi: 10.1007/s11102-013-0484-2. PMID: 23564339; PMCID: PMC3942630.

Seguici sui social media​:

Questo sito Web è destinato agli utenti al di fuori degli Stati Uniti e del Regno Unito. Le informazioni fornite in questo sito sono destinate a scopi educativi e non devono essere utilizzate in sostituzione di una visita, un consulto o un consiglio del medico o di un altro operatore sanitario. Questo sito è finanziato da Recordati Rare Diseases, e i personaggi che appaiono sono veri pazienti e operatori sanitari. Non vengono divulgate informazioni mediche personali.

Tutte le foto scattate dal fotografo sono sponsorizzate da Recordati e concesse in esclusiva a Recordati da Stefano Schirato. Copyright © 2023 Recordati AG. Tutti i diritti riservati. EMEA-LAC/CH/ENV/HCP-PAT/Feb-2023/39

I tuoi commenti